IDH1-R132G Antibody / Isocitrate Dehydrogenase R132G mutant
Selected Variant
GTR18716906
Size: 100 µg
The gene represented in this entry is involved in disease pathogenesis. Mutations affecting Arg-132 are tissue-specific, and suggest that this residue plays a unique role in the development of high-grade gliomas. Mutations of Arg-132 to Cys, His, Leu or Ser abolish magnesium binding and abolish the conversion of isocitrate to alpha-ketoglutarate. Instead, alpha-ketoglutarate is converted to R (-) -2-hydroxyglutarate. Elevated levels of R (-) -2-hydroxyglutarate are correlated with an elevated risk of malignant brain tumors. Genetic variations are associated with cartilaginous tumors such as enchondroma or chondrosarcoma. Mutations of Arg-132 to Cys, Gly or His abolish the conversion of isocitrate to alpha-ketoglutarate. Instead, alpha-ketoglutarate is converted to R (-) -2-hydroxyglutarate.
Product Specifications
UniProt
O75874
Reactivity
Human
Immunogen
A recombinant partial protein from human IDH1 protein with the R132G mutation was used as the immunogen for the IDH1-R132G antibody.
Clonality
Recombinant
Clone
IDH1.R132G/13054R
Conjugation
Unconjugated
Field of Research
Metabolism Research
Purification
Protein A affinity
Dilution
Immunohistochemistry (FFPE) : 1-2ug/ml, Western blot: 2-4ug/ml
Storage Conditions
Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.
Notes
For research use only.
Applications Notes
Optimal dilution of the IDH1-R132G antibody should be determined by the researcher.
Tested Applications
IHC-P, WB
Host or Source
Rabbit
Preservative
1 mg/ml in 1X PBS; rAlbumin free, sodium azide free
Isotype
Rabbit IgG, kappa
Price
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog